Harlan Weisman, Flame Biosciences CEO

A phar­ma ex­ec gets $100M to chase a can­cer-fight­ing idea un­cov­ered in a 2017 No­var­tis study

Har­lan Weis­man, a long­time phar­ma and biotech ex­ec­u­tive, was start­ing up his lat­est project in the sum­mer of 2017 when he caught wind of a ma­jor study com­ing out of No­var­tis. A 10,000-per­son study pub­lished in The New Eng­land Jour­nal of Med­i­cine showed that a No­var­tis an­ti­body that blocked one of the key path­ways of in­flam­ma­tion, in­ter­leukin 1 be­ta, sig­nif­i­cant­ly re­duced the odds of ma­jor car­dio­vas­cu­lar events like heart at­tack and stroke in high-risk pa­tients.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.